Evidence map›Paper›PMID 34067456›Full record

ArticleCancers2021

Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets.

Magdalena Rausch, Léa Blanc, Olga De Souza Silva, Olivier Dormond, Arjan W Griffioen, Patrycja Nowak-Sliwinska

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Magdalena RauschSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-8485-9220
Léa BlancSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-0289-6934
Olga De Souza SilvaDepartment of Visceral Surgery, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-1314-536X
Olivier DormondDepartment of Visceral Surgery, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-6418-1782
Arjan W GriffioenAngiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
Patrycja Nowak-SliwinskaSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-8299-0444
University of Geneva · CHUniversity of Lausanne · CHAmsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two-dimensional cell culture-based platforms are easy and reproducible, however, they do not resemble the heterotypic cell-cell interactions or the complex tumor microenvironment. These parameters influence the treatment response and the cancer cell fate. Platforms to study the efficacy of anti-cancer treatments and their impact on the tumor microenvironment are currently being developed. In this study, we established robust, reproducible, and easy-to-use short-term spheroid cultures to mimic clear cell renal cell carcinoma (ccRCC). These 3D co-cultures included human endothelial cells, fibroblasts, immune cell subsets, and ccRCC cell lines, both parental and sunitinib-resistant. During spheroid formation, cells induce the production and secretion of the extracellular matrix. We monitored immune cell infiltration, surface protein expression, and the response to a treatment showing that the immune cells infiltrated the spheroid co-cultures within 6 h. Treatment with an optimized drug combination or the small molecule-based targeted drug sunitinib increased immune cell infiltration significantly. Assessing the therapeutic potential of this drug combination in this platform, we revealed that the expression of PD-L1 increased in 3D co-cultures. The cost- and time-effective establishment of our 3D co-culture model and its application as a pre-clinical drug screening platform can facilitate the treatment validation and clinical translation.

Indexed as

3D co-culturescombination therapyheterotypic spheroidsimmune cellsimmunotherapyinfiltrationPD-L1renal cell carcinomasunitinib

Identifiers

PMID34067456
PMCPMC8197009
OpenAlexW3165590083

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.